

Question: Should SADI-S vs. sleeve gastrectomy be used for weight loss?

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	SADI-S	sleeve gastrectomy	Relative (95% CI)	Absolute (95% CI)		
EWL (follow up: 12 months; assessed with: %)												
1	observational studies	serious	not serious	not serious	serious	none	26	29	-	MD 19.7 higher (8.33 higher to 31.07 higher)	⊕○○○ VERY LOW	IMPORTANT
Mortality (follow up: 30 days)												
1	observational studies	serious	not serious	not serious	serious	none	0/89 (0.0%)	0/89 (0.0%)	RD 0.00 (-0.02 to 0.02)	0 fewer per 1.000 (from 20 fewer to 20 more)	⊕○○○ VERY LOW	CRITICAL
Morbidity (follow up: 30 days)												
1	observational studies	serious	not serious	not serious	serious	none	13/89 (14.6%)	8/89 (9.0%)	OR 1.73 (0.68 to 4.41)	56 more per 1.000 (from 27 fewer to 214 more)	⊕○○○ VERY LOW	CRITICAL
HbA1c (follow up: 12 months; assessed with: %)												
1	observational studies	serious	not serious	not serious	not serious	none	26	26	-	MD 0 (0.38 lower to 0.38 higher)	⊕○○○ VERY LOW	IMPORTANT
Hypertension (follow up: 12 months)												

1	observational studies	serious	not serious	not serious	very serious	none	2/26 (7.7%)	4/29 (13.8%)	OR 0.52 (0.09 to 3.11)	61 fewer per 1.000 (from 124 fewer to 194 more)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	--------------	------	-------------	--------------	----------------------------------	---	------------------	-----------

Dyslipidemia (follow up: 12 months)

1	observational studies	serious	not serious	not serious	very serious	none	1/26 (3.8%)	6/29 (20.7%)	OR 0.15 (0.02 to 1.37)	169 fewer per 1.000 (from 202 fewer to 56 more)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	--------------	------	-------------	--------------	----------------------------------	---	------------------	-----------

SBP (follow up: 12 months; assessed with: mmHg)

1	observational studies	serious	not serious	not serious	not serious	none	26	29	-	MD 1 higher (8.25 lower to 10.25 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	-------------	------	----	----	---	--	------------------	-----------

DBP (follow up: 12 months; assessed with: mmHg)

1	observational studies	serious	not serious	not serious	not serious	none	26	29	-	MD 2.5 higher (4.81 lower to 9.81 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	-------------	------	----	----	---	---	------------------	-----------

Triglycerides (follow up: 12 months; assessed with: mg/dL)

1	observational studies	serious	not serious	not serious	very serious	none	26	29	-	MD 17.1 lower (33.57 lower to 0.63 lower)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	--------------	------	----	----	---	---	------------------	-----------

HDL (follow up: 12 months; assessed with: mg/dL)

1	observational studies	serious	not serious	not serious	not serious	none	26	29	-	MD 1.9 higher (3.95 lower to 7.75 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	-------------	------	----	----	---	---	------------------	-----------

LDL (follow up: 12 months; assessed with: mg/dL)

1	observational studies	serious	not serious	not serious	serious	none	26	29	-	MD 14.4 lower (30.19 lower to 1.39 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	---------	------	----	----	---	--	------------------	-----------

Total cholesterol (follow up: 12 months; assessed with: mg/dL)

1	observational studies	serious	not serious	not serious	not serious	none	26	29	-	MD 11.1 lower (27 lower to 4.8 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	-------------	------	----	----	---	--	------------------	-----------

Iron (follow up: 12 months; assessed with: ug/dL)

1	observational studies	serious	not serious	not serious	serious	strong association	26	29	-	MD 34.1 lower (59 lower to 9.2 lower)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	---------	--------------------	----	----	---	---	------------------	-----------

Hemoglobin (follow up: 12 months; assessed with: g/dL)

1	observational studies	serious	not serious	not serious	serious	none	26	29	-	MD 0.9 lower (2.01 lower to 0.21 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	---------	------	----	----	---	--	------------------	-----------

Albumin (follow up: 12 months; assessed with: mg/dL)

1	observational studies	serious	not serious	not serious	not serious	none	26	29	-	MD 0 (0.13 lower to 0.13 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	-------------	------	----	----	---	--	------------------	-----------

Calcium (follow up: 12 months; assessed with: mg/dL)

1	observational studies	serious	not serious	not serious	very serious	none	26	29	-	MD 0.2 lower (0.39 lower to 0.01 lower)	⊕○○○ VERY LOW	IMPORTANT
---	-----------------------	---------	-------------	-------------	--------------	------	----	----	---	---	------------------	-----------

CI: Confidence interval; MD: Mean difference; OR: Odds ratio